A sugar-based phase-transitioning delivery system for bone tissue-engineering

European Cells and Materials

Volumn 26, Issue , 2013, Pages 208-221

  Cheng, T L ^a,b   Valtchev, P ^c   Murphy, C M ^a   Cantrill, L C ^a,b   Dehghani, F ^c   Little, D G ^a,b   Schindeler, A ^a,b  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Bisphosphonate; Bone tissue engineering; Hydroxyapatite; Injectable scaffold; Sucrose acetate isobutyrate

Indexed keywords

COLLAGEN; HYDROXYAPATITE; INFUSE; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; SUCROSE ACETATE ISOBUTYRATE; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING ASSAY; BONE GRAFT; BONE GROWTH; BONE MASS; BONE TISSUE; CELL PROLIFERATION; CELL VIABILITY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ECTOPIC TISSUE; FEMALE; HISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OSSIFICATION; RADIOGRAPHY; RISK ASSESSMENT; RISK REDUCTION; TISSUE ENGINEERING;

ANIMALS; BONE MORPHOGENETIC PROTEIN 2; BONE REGENERATION; CELL CULTURE TECHNIQUES; COLLAGEN; DIPHOSPHONATES; DRUG DELIVERY SYSTEMS; HYDROXYAPATITES; IMIDAZOLES; MICE; MICE, INBRED C57BL; SUCROSE; TISSUE DISTRIBUTION; TISSUE ENGINEERING;

EID: 84886246996     PISSN: 14732262     EISSN: None     Source Type: Journal    
DOI: 10.22203/eCM.v026a15     Document Type: Article

References (51)

1. Adachi S, Matsushima-Nishiwaki R, Kato K, Natsume H (2011) Enhancement of basic fibroblast growth factor-stimulated VEGF synthesis by Wnt3a in osteoblasts. Int J Mol Med 27: 859-864.
2. Argintar E, Edwards S, Delahay J (2011) Bone morphogenetic proteins in orthopaedic trauma surgery. Injury 42: 730-734.
3. Aro HT, Govender S, Patel AD, Hernigou P, Perera de Gregorio A, Popescu GI, Golden JD, Christensen J, Valentin A (2011) Recombinant human bone morphogenetic protein-2: A randomized trial in open tibial fractures treated with reamed nail fixation. J Bone Joint Surg 93: 801-808.
4. Axelrad TW, Einhorn TA (2009) Bone morphogenetic proteins in orthopaedic surgery. Cytokine Growth Factor Rev 20: 481-488.
5. Bose S, Roy M, Bandyopadhyay A (2012) Recent advances in bone tissue engineering scaffolds. Trends Biotechnol 30: 546-554.
6. Burdick JA, Anseth KS (2002) Photoencapsulation of osteoblasts in injectable RGD-modified PEG hydrogels for bone tissue engineering. Biomaterials 23: 4315-4323.
7. Carr D, Yu NYC, Fitzpatrick J, Peacock L, Mikulec K, Ruys AJ, Cooper-White JC, Little DG, Schindeler A (2012) Synergy between rhBMP-2 and IKK-Inhibitor PS-1145 delivered via a porous biodegradable polymer implant. J Tissue Sci Eng. S1:003.
8. Carragee EJ, Hurwitz EL, Weiner BK (2011) A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J 11: 471-491.
9. Davison N, Yuan H, de Bruijn JD, Barrere-de Groot F (2012) In vivo performance of microstructured calcium phosphate formulated in novel water-free carriers. Acta Biomater 8: 2759-2769.
10. D'Este M, Eglin D (2013) Hydrogels in calcium phosphate moldable and injectable bone substitutes: Sticky excipients or advanced 3-D carriers? Acta Biomater 9: 5421-5430.
11. Doan TKP, Park KS, Kim HK, Park DS, Kim JH, Yoon TR (2012) Inhibition of JNK and ERK pathways by SP600125-and U0126-enhanced osteogenic differentiation of bone marrow stromal cells. Tissue Engineering and Regenerative Medicine 9: 283-294.
12. Ebraheim NA, Elgafy H, Xu R (2001) Bone-graft harvesting from iliac and fibular donor sites: techniques and complications. J Am Acad Orthopaed Surg 9: 210-218.
13. Friess W, Uludag H, Foskett S, Biron R, Sargeant C (1999) Characterization of absorbable collagen sponges as rhBMP-2 carriers. Int J Pharm 187: 91-99.
14. Giannoudis PV, Einhorn TA, Marsh D (2007a) Fracture heating: The diamond concept. Injury 38: S3-S6.
15. Giannoudis PV, Kanakaris NK, Einhorn TA (2007b) Interaction of bone morphogenetic proteins with cells of the osteoclast lineage: review of the existing evidence. Osteoporosis Int 18: 1565-1581.
16. Hadj A, Nicholson D, Moodie J, Turner R, Watts R, Abrouk N, Langecker P, Lissin D (2009) SABER™ Bupivacaine, a novel extended-release formulation of bupivacaine for postoperative pain control demonstrates dose-response, safety and no impact on surgical wound healing following inguinal herniorrhapy. In: Proc Am Coll Surg 95th Annual Clinical Congress, (http://www.durect.com/pdf/ACS2009SABERPoster.pdf)
17. Hadj A, Hadj A, Hadj A, Rosenfeldt F, Nicholson D, Moodie J, Turner R, Watts R, Fletcher I, Abrouk N, Lissin D (2012) Safety and efficacy of extended-release bupivacaine local anaesthetic in open hernia repair: a randomized controlled trial. ANZ J Surg 82: 251-257.
18. Halvorson JJ, Barnett M, Jackson B, Birkedal JP (2012) Risk of septic knee following retrograde intramedullary nailing of open and closed femur fractures. J Orthopaed Surg Res 7: 7.
19. Han DK, Hubbell JA (1996) Lactide-based poly (ethylene glycol) polymer networks for scaffolds in tissue engineering. Macromolecules 29: 5233-5235.
20. Im GI, Tae SK (2005) Distal metaphyseal fractures of tibia: A prospective randomized trial of closed reduction and intramedullary nail versus open reduction and plate and screws fixation. J Trauma 59: 1219-1223.
21. Kartsogiannis V, Ng KW (2004) Cell lines and primary cell cultures in the study of bone cell biology. Mol Cell Endocrinol 228: 79-102.
22. Kato M, Toyoda H, Namikawa T, Hoshino M, Terai H, Miyamoto S, Takaoka K (2006) Optimized use of a biodegradable polymer as a carrier material for the local delivery of recombinant human bone morphogenetic protein-2 (rhBMP-2). Biomaterials 27: 2035-2041.
23. Keskin DS, Tezcaner A, Korkusuz P, Korkusuz F, Hasirci V (2005) Collagen-chondroitin sulfate-based PLLA-SAIB-coated rhBMP-2 delivery system for bone repair. Biomaterials 26: 4023-4034.
24. Krebs MD, Sutter KA, Lin ASP, Guldberg RE, Alsberg E (2009) Injectable poly(lactic-co-glycolic) acid scaffolds with in situ pore formation for tissue engineering. Acta Biomater 5: 2847-2859.
25. Lawson MA, Xia Z, Barnett BL, Triffitt JT, Phipps RJ, Dunford JE, Locklin RM, Ebetino FH, Russell RGG (2010) Differences between bisphosphonates in binding affinities for hydroxyapatite. J Biomed Mater Res B Appl Biomater 92B: 149-155.
26. Lin X, Yang SS, Gou JX, Zhao MM, Zhang Y, Qi N, He HB, Cai CF, Tang X, Guo PH (2012) A novel risperidone-loaded SAIB-PLGA mixture matrix depot with a reduced burst release: effects of solvents and PLGA on drug release behaviors in vitro/in vivo. J Mater Sci Mater Med 23: 443-455.
27. Little DG, McDonald M, Bransford R, Godfrey CB, Amanat N (2005) Manipulation of the anabolic and catabolic responses with OP-1 and zoledronic acid in a rat critical defect model. J Bone Miner Res 20: 2044-2052.
28. Little DG, Ramachandran M, Schindeler A (2007) The anabolic and catabolic responses in bone repair. J Bone Joint Surg Br 89B: 425-433.
29. Lu YX, Yu YL, Tang X (2007) Sucrose acetate isobutyrate as an in situ forming system for sustained risperidone release. J Pharm Sci 96: 3252-3262.
30. Lutolf MP, Weber FE, Schmoekel HG, Schense JC, Kohler T, Müller R, Hubbell JA (2003) Repair of bone defects using synthetic mimetics of collagenous extracellular matrices. Nat Biotechnol 21: 513-518.
31. Maeda H, Sano A, Fujioka K (2004) Controlled release of rhBMP-2 from collagen minipellet and the relationship between release profile and ectopic bone formation. International J Pharm 275: 109-122.
32. Martinez-Sanz E, Varghese OP, Kisiel M, Engstrand T, Reich KM, Bohner M, Jonsson KB, Kohler T, Muller R, Ossipov DA, Hilborn J (2012) Minimally invasive mandibular bone augmentation using injectable hydrogels. J Tissue Eng Regen Med 6: s15-s23.
33. Miyamoto S, Takaoka K (1993) Bone induction and bone repair by composites of bone morphogenetic protein and biodegradable synthetic polymers. In: Proc Ann Chir Gynaecol Suppl, pp 69.
34. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RGG, Ebetino FH (2006) Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite. Bone 38: 617-627.
35. O'Brien FJ (2011) Biomaterials & scaffolds for tissue engineering. Mater Today 14: 88-95.
36. Okumu FW, Dao LN, Fielder PJ, Dybdal N, Brooks D, Sane S, Cleland JL (2002) Sustained delivery of human growth hormone from a novel gel system: SABER (TM). Biomaterials 23: 4353-4358.
37. Packhaeuser CB, Schnieders J, Oster CG, Kissel T (2004) In situ forming parenteral drug delivery systems: an overview. Eur J Pharm Biopharm 58: 445-455.
38. Peled E, Boss J, Bejar J, Zinman C, Seliktar D (2007) A novel poly(ethylene glycol)-fibrinogen hydrogel for tibial segmental defect repair in a rat model. J Biomed Mater Res A 80A: 874-884.
39. Podgorski I (2009) Future of anticathepsin K drugs: dual therapy for skeletal disease and atherosclerosis? Future Med Chem 1: 21-34.
40. Schindeler A, Little DG (2005) Osteoclasts but not osteoblasts are affected by a calcified surface treated with zoledronic acid in vitro. Biochem Biophys Res Commun 338: 710-716.
41. Schindeler A, Morse A, Peacock L, Mikulec K, Yu NYC, Liu RJ, Kijumnuayporn S, McDonald MM, Baldock PA, Ruys AJ, Little DG (2010) Rapid cell culture and pre-clinical screening of a transforming growth factor-beta (TGF-beta) inhibitor for orthopaedics. BMC Musculoskel Disord 11: 105.
42. Seiler JG 3rd, Johnson J (2000) Iliac crest autogenous bone grafting: donor site complications. J South Orthopaed Assoc 9: 91-97.
43. Stoeger T, Proetzel G, Welzel H, Papadimitriou A, Dony C, Balling R, Hofmann C (2003) In situ gene expression analysis during BMP2-induced ectopic bone formation in mice shows simultaneous endochondral and intramembranous ossification. Growth Factors 20: 197-210.
44. Stroup GB, Lark MW, Veber DF, Bhattacharyya A, Blake S, Dare LC, Erhard KF, Hoffman SJ, James IE, Marquis RW, Ru Y, Vasko-Moser JA, Smith BR, Tomaszek T, Gowen M (2001) Potent and selective inhibition of human Cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate. J Bone Miner Res 16: 1739-1746.
45. Vaccaro AR (2002) The role of the osteoconductive scaffold in synthetic bone graft. Orthopedics 25: S571-S578.
46. von Metzler I, Krebbel H, Hecht M, Manz RA, Fleissner C, Mieth M, Kaiser M, Jakob C, Sterz J, Kleeberg L, Heider U, Sezer O (2007) Bortezomib inhibits human osteoclastogenesis. Leukemia 21: 2025-2034.
47. WHO (1997) Evaluation of Certain Food Additives and Contaminants. WHO Technical Report Series 868. WHO, Geneva, pp 797.
48. Wright HM, Clish CB, Mikami T, Hauser S, Yanagi K, Hiramatsu R, Serhan CN, Spiegelman BM (2000) A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation. J Biol Chem 275: 1873-1877.
49. Yamamoto M, Takahashi Y, Tabata Y (2006) Enhanced bone regeneration at a segmental bone defect by controlled release of bone morphogenetic protein-2 from a biodegradable hydrogel. Tissue Eng 12: 1305-1311.
50. Zhang MYH, Ranch D, Pereira RC, Armbrecht HJ, Portale AA, Perwad F (2012) Chronic Inhibition of ERK1/2 Signaling improves disordered bone and mineral metabolism in hypophosphatemic (Hyp) mice. Endocrinology 153: 1806-1816.
51. Zhang W, Wang X, Wang S, Zhao J, Xu L, Zhu C, Zeng D, Chen J, Zhang Z, Kaplan DL, Jiang X (2011) The use of injectable sonication-induced silk hydrogel for VEGF(165) and BMP-2 delivery for elevation of the maxillary sinus floor. Biomaterials 32: 9415-9424.